Research programme: multi-specific antibody therapeutics - Numab Therapeutics/Ono Pharmaceutical
Alternative Names: ND 023Latest Information Update: 28 Sep 2023
At a glance
- Originator Numab; Ono Pharmaceutical
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for research development in Cancer in Japan (Parenteral)
- 28 Sep 2023 No recent reports of development identified for research development in Cancer in Switzerland (Parenteral)
- 31 Mar 2022 Ono Pharmaceutical in-licenses multi-specific antibody therapeutics from Numab Therapeutics